Armen Asatryan

Dr. Armen Asatryan


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2018 in Viruses
Verified
Journal Article
Open access
PDF file
TNTeresa Ng
Teresa Ng
TPTami Pilot-Matias
Tami Pilot-Matias
RTRakesh Tripathi
Rakesh Tripathi
GSGretja Schnell
Gretja Schnell
PKPreethi Krishnan
Preethi Krishnan
CCChristine Collins
Christine Collins
Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals. This report describes the baseline polymorphisms and treatment-emergent substitutions in NS3 or NS5A detected in samples from HCV genotype 1-infected patients receiving 3-day monotherapy of glecaprevir or pibrentasvir, respectively. None of the NS3 polymorphisms detected in the 47 baseline samples collected prior to glecaprevir monotherapy conferred reduced susceptibility to glecaprevir. The NS3 A156T substitution, which conferred resistance to glecaprevir but had low replication efficiency, emerged in one genotype 1a-infected patient among the 35 patients with available post-baseline sequence data. Baseline NS5A polymorphisms were detected in 12 of 40 patients prior to pibrentasvir monotherapy; most polymorphisms were single-position NS5A amino acid substitutions that did not confer resistance to pibrentasvir. Among the 19 patients with available post-baseline NS5A sequence data, 3 had treatment-emergent NS5A substitutions during pibrentasvir monotherapy. All treatment-emergent NS5A substitutions were linked multiple-position, almost exclusively double-position, substitutions that conferred resistance to pibrentasvir. Replicons engineered with these double-position substitutions had low replication efficiency. In conclusion, resistance-conferring substitutions emerged in a small number of genotype 1-infected patients during glecaprevir or pibrentasvir monotherapy; unlike other NS5A inhibitors, pibrentasvir did not select single-position NS5A substitutions during monotherapy.

1 April 2016 in Gastroenterology
Verified
Journal Article
Closed access
EGEdward Gane
Edward Gane
JLJacob Lalezari
Jacob Lalezari
AAArmen Asatryan
Armen Asatryan
SGSusan Greenbloom
Susan Greenbloom
THTarek I. Hassanein
Tarek I. Hassanein
FMFederico Mensa
Federico Mensa

1 April 2016 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
FPFred Poordad
Fred Poordad
FFFranco Felizarta
Franco Felizarta
SWStanley Wang
Stanley Wang
AAArmen Asatryan
Armen Asatryan
THTarek I. Hassanein
Tarek I. Hassanein
FMFederico Mensa
Federico Mensa